Christen N. Martino

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.

E. Warren, R. Lynch, M. Shadman, 2021, The Lancet. Haematology.